These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25129342)

  • 1. Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs.
    Plotkin A; Volmar CH; Wahlestedt C; Ayad N; El-Ashry D
    Breast Cancer Res Treat; 2014 Sep; 147(2):249-63. PubMed ID: 25129342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype.
    Shah SH; Miller P; Garcia-Contreras M; Ao Z; Machlin L; Issa E; El-Ashry D
    Cancer Biol Ther; 2015; 16(11):1671-81. PubMed ID: 26186233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
    Li G; Xie Q; Yang Z; Wang L; Zhang X; Zuo B; Zhang S; Yang A; Jia L
    Int J Cancer; 2019 Dec; 145(12):3285-3298. PubMed ID: 31111958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
    Zhou Q; Atadja P; Davidson NE
    Cancer Biol Ther; 2007 Jan; 6(1):64-9. PubMed ID: 17172825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
    Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
    Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.
    Feng W; Lu Z; Luo RZ; Zhang X; Seto E; Liao WS; Yu Y
    Int J Cancer; 2007 Apr; 120(8):1664-8. PubMed ID: 17230502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
    Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
    Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
    Sharma D; Saxena NK; Davidson NE; Vertino PM
    Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.
    Yang X; Ferguson AT; Nass SJ; Phillips DL; Butash KA; Wang SM; Herman JG; Davidson NE
    Cancer Res; 2000 Dec; 60(24):6890-4. PubMed ID: 11156387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.
    Macaluso M; Cinti C; Russo G; Russo A; Giordano A
    Oncogene; 2003 Jun; 22(23):3511-7. PubMed ID: 12789259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor.
    Mazumdar A; Wang RA; Mishra SK; Adam L; Bagheri-Yarmand R; Mandal M; Vadlamudi RK; Kumar R
    Nat Cell Biol; 2001 Jan; 3(1):30-7. PubMed ID: 11146623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.
    Vesuna F; Lisok A; Kimble B; Domek J; Kato Y; van der Groep P; Artemov D; Kowalski J; Carraway H; van Diest P; Raman V
    Oncogene; 2012 Jul; 31(27):3223-34. PubMed ID: 22056872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.
    Arabsolghar R; Azimi T; Rasti M
    Mol Biol Rep; 2013 Mar; 40(3):2617-25. PubMed ID: 23242655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
    Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
    Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
    Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scriptaid effects on breast cancer cell lines.
    Giacinti L; Giacinti C; Gabellini C; Rizzuto E; Lopez M; Giordano A
    J Cell Physiol; 2012 Oct; 227(10):3426-33. PubMed ID: 22213035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer.
    Shankar E; Pandey M; Verma S; Abbas A; Candamo M; Kanwal R; Shukla S; MacLennan GT; Gupta S
    Mol Carcinog; 2020 Aug; 59(8):955-966. PubMed ID: 32391971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway.
    Suzuki K; Oneyama C; Kimura H; Tajima S; Okada M
    J Biol Chem; 2011 May; 286(18):15698-706. PubMed ID: 21388951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.